SCHEMBL2610275

SCHEMBL2610275

CC(=O)c1sc2cc(-c3ccccc3)ccc2c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 2/20 0.45
▸ RXFP1 Q9HBX9 2/20 0.44
▸ PRNP P04156 1/20 0.44
▸ MAPT P10636 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ PIK3CG P48736 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GPR35 Q9HC97 1/20 0.43
▸ BRD4 O60885 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ BCL2L1 Q07817 1/20 0.40
▸ LIMK1 P53667 2/20 0.40
▸ CES2 O00748 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TBXAS1 P24557 1/20 0.38
▸ TNKS2 Q9H2K2 1/20 0.38
▸ APOBEC3A P31941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2610250 0.79 RXFP1 (0.61) MCL1RXFP1PRNPMAPTKDM4E
SCHEMBL13713781 0.77 LIMK1 (0.44) MCL1PIK3CGLIMK1TNKS2ABL1
SCHEMBL6840354 0.77 GPR35 (0.55) MCL1RXFP1PRNPPKMSMN1; SMN2
SCHEMBL2951733 0.77 RXRA (0.45) RXFP1PRNPKDM4ELMNASMN1; SMN2
SCHEMBL121901 0.76 MCL1 (0.57) MCL1RXFP1MAPTKDM4ELMNA
SCHEMBL21950990 0.74 GPR35 (0.41) MCL1RXFP1PRNPMAPTKDM4E
SCHEMBL6840332 0.73 DYRK1A (0.44) MCL1MAPTSMN1; SMN2GPR35BCL2L1
SCHEMBL10110898 0.72 LIMK1 (0.51) MAPTKDM4ELMNAPIK3CGSMN1; SMN2
SCHEMBL12562737 0.72 LIMK1 (0.51) MAPTKDM4ELMNAPIK3CGSMN1; SMN2
SCHEMBL17340882 0.72 LIMK1 (0.40) MCL1PIK3CGLIMK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748417-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2014-06-10 — — US disclosed
US-8575363-B2 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2013-11-05 — — US disclosed
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2013-08-01 — — US disclosed
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (BE) 2012-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196970-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MCL1 3401/4885RXFP1 877/4885PRNP 1005/4885
US-20120101081-A1 AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, MGLL MCL1 3401/4885RXFP1 877/4885PRNP 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback